glp-1 obesity drug news A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio glp-1 obesity drug news today

[DOI] [PMC free article] [PubMed] [Google Scholar] 149.El K, Douros JD, Willard FS, et al

doi: 10.1016/j.jand.2024.10.023

GLP-1 RAs significantly reduced the risk of MACE compared with placebo (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.770.98) in HF coexisting with T2DM

21,22 Although clear protective benefits in diabetic retinopathy development and impact on disease progression remain under investigation, GLP-1RAs have been shown to reduce complications from chronic diabetes, such as retinal vein occlusion and cardiovascular disease

Your care should be, too

This is not a prescription medication but should be discussed if you take other medications